Biomerica Board of Directors Adds New Member<>tp://Al
NEWPORT BEACH, California, July 17, 2007 – Biomerica, Inc. (OTC BB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that its board of directors has increased the size of the board from five to six members and elected John Roehm, President & CEO of Mollen Immunization Clinics of North America to the board. From 1989 to 2006, Mr. Roehm served in a broad range of leadership positions with Albertsons / American Stores (Sav-on & Osco) including its Director of Pharmacy Marketing since 1999. He holds a B.S. degree in Pharmacy from Massachusetts College of Pharmacy.
“John’s broad experience in chain drug pharmacy marketing and management will bring an enormous wealth of OTC and consumer knowledge to our Company,” said Biomerica CEO and Chairman Zack Irani. “We are pleased that John has joined our Board as we increase our focus on the OTC drug store market.”
“Biomerica is well positioned to take advantage of the growth in the consumer healthcare market,” Mr. Roehm said. “I look forward to contributing to the Company as it grows.”
The Company also recently elected Jane F. Emerson, M.D., Ph.D., Chief of Clinical Pathology and Vice-Chair for Clinical Affairs, Department of Pathology and Laboratory Medicine University of California, Irvine, to the board.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.